Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
|Articles|November 1, 2004
- Volume 0 0
Errata
Advertisement
The article on Home DiagnosticKits in the September 2004 issue ofPharmacy Times should have saidthat the FDA has cleared home testingkits for consumer use.
The article on Fluoroquinolonesin the September issue should havereferred to nalidixic acid as aquinolone.
An error in editing resulted in misinformationin the article, Statins andDiabetes (October 2004). The tableshould have said that there are currently6 statins on the market. Ezetimibe(Zetia) and the combination productezetimibe/simvastatin (Vytorin)should not have been included.
Articles in this issue
about 22 years ago
Geriatric Pharmacologyabout 22 years ago
Management of Bacterial Rhinosinusitisabout 22 years ago
Early RA Treatment Proves Beneficialabout 22 years ago
Topical Creams Work Temporarilyabout 22 years ago
Mental Anguish Is Common with Arthritisabout 22 years ago
Overview of Astrocytomas?The Pharmacist's Perspectiveabout 22 years ago
Scanner Detects Hand Arthritisabout 22 years ago
OA: All in the Familyabout 22 years ago
Sheriff Sues Board for Searching His Rx Records Without a Warrantabout 22 years ago
Restricting the Sale of Cold MedicationsAdvertisement
Related to this article
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
How Stanford Pharmacists Help Close Heart Failure Therapy Gaps
3
GLP-1s and Obesity Care: Cardiorenal Outcomes, Prescribing Considerations, and Access Barriers
4
GLP-1 Receptor Agonists and Cancer: Considerations for Specialty Pharmacists
5